botulinum toxin A injection (AI-09)
/ Eirion
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 01, 2026
AI-09 In Subjects With Glabellar Lines, GL-101
(clinicaltrials.gov)
- P1/2 | N=96 | Completed | Sponsor: Eirion Therapeutics Inc. | N=72 ➔ 96
Enrollment change
January 08, 2026
A Study to Evaluate AI-09 In Participants With Glabellar Lines
(clinicaltrials.gov)
- P2 | N=68 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc.
New P2 trial
August 01, 2024
AI-09 In Subjects With Glabellar Lines, GL-101
(clinicaltrials.gov)
- P1/2 | N=72 | Completed | Sponsor: Eirion Therapeutics Inc. | Active, not recruiting ➔ Completed
Trial completion
January 25, 2024
AI-09 In Subjects With Glabellar Lines, GL-101
(clinicaltrials.gov)
- P1/2 | N=72 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed
December 06, 2023
AI-09 In Subjects With Glabellar Lines, GL-101
(clinicaltrials.gov)
- P1/2 | N=72 | Recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: Jan 2024 ➔ May 2024 | Trial primary completion date: Jan 2024 ➔ May 2024
Trial completion date • Trial primary completion date
June 22, 2023
AI-09 In Subjects With Glabellar Lines, GL-101
(clinicaltrials.gov)
- P1/2 | N=72 | Recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: Sep 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2023 ➔ Jan 2024
Trial completion date • Trial primary completion date
1 to 6
Of
6
Go to page
1